Biopharmaceutics classification system

Systematic Reviews in Pharmacy

Volumn 1, Issue 1, 2010, Pages 62-69

  Chavda, H V ^a   Patel, C N ^a   Anand, I S ^a  

^a HEMCHANDRACHARYA NORTH GUJARAT UNIVERSITY   (India)

Author keywords

Biopharamceutics classification system; Biowaiver; Dissolution; Permeability; Solubility

Indexed keywords

ACICLOVIR; ATENOLOL; CAPTOPRIL; CARBAMAZEPINE; CHLOROQUINE; CIMETIDINE; CYCLOSPORIN A; DANAZOL; DILTIAZEM; ELLAGIC ACID; FRAMYCETIN; FUROSEMIDE; GLIBENCLAMIDE; KETOCONAZOLE; METFORMIN; METOPROLOL; NIFEDIPINE; PACLITAXEL; PARACETAMOL; PHENYTOIN; PROPRANOLOL; RANITIDINE; RITONAVIR; SAQUINAVIR; THEOPHYLLINE; TROGLITAZONE; UBIDECARENONE; VERAPAMIL;

BIOPHARMACEUTICS CLASSIFICATION SYSTEM; DRUG ABSORPTION; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG RELEASE; DRUG RESEARCH; DRUG SOLUBILITY; HUMAN; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; PHARMACOLOGICAL PROCEDURES; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW;

EID: 78349304097     PISSN: 09758453     EISSN: 09762779     Source Type: Journal    
DOI: 10.4103/0975-8453.59514     Document Type: Review

References (30)

1. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutics drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20.
2. Helga M. The Biopharmaceutical Classification System (BCS) and its usage. Drugs Made in Germany 2002;45:63-5.
3. Dressman J, Butler J, Hempenstall J, Reppas C. The BCS: Where do we go from here? Pharmaceut Technol 2001;25:68-76.
4. Gothoskar AV. Biopharmaceutical classification system of drugs [online]. Pharmaceut Rev. Availablen from: URL: http://www.pharmainfo.net/reviews/ biopharmaceutical-classification-drugs. [last cited on 2005 Feb 12].
5. Center for Drug Evaluation, USFDA. Guidance for industry: Waiver of In vivo bioavailability and bioequivalence for immediate release solid oral dosage forms based on a biopharmaceutics classification system. August 2000.
6. Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations, Fortieth Report. Geneva, World Health Organization. WHO Technical Report Series, No. 937, Annex 7: 2000. p. 347-390.
7. Committee for Medicinal Products for Human Use. Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1), July 2008.
8. Sinko PJ, Leesman GD, Amidon GL. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharmaceut Res 1991;8:979-88.
9. Lennerns H, Knutson L, Knutson T, Hussain A, Lesko L, Salmonson T, et al. The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: Experience from a regional perfusion technique. Eur J Pharm Sci 2002;15:271-7. (Pubitemid 34229141)
10. Bjarnason I, Smethurst P, Fenn CG, Lee CE, Menzies IS, Levi AJ. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci 1989;34:407-11. (Pubitemid 19088782)
11. Farthing MJ. Disease-related animal models for optimising oral rehydration solution composition. Acta Paediatr 2008;78:23-30.
12. Scherer D, Mooren FC, Kinne RK, Kreuter J. In Vitro permeability of PBCA nanoparticles through porcine small intestine. J Drug Target 1993;1:21-7.
13. Yee S. In Vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res 1997;14:763-6. (Pubitemid 27281671)
14. Grs MC, Julian B, Bourri M, Meunier V, Roques C, Berger M, et al. Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: Comparison with the parental Caco-2 cell line. Pharm Res 1998;15:726-33. (Pubitemid 28275649)
15. Center for Drug Evaluation, USFDA. Guidance for Industry: Immediate Release Solid Oral Dosage Forms: Scale Up and Post Approval Changes. Nov 1995.
16. Kanfer I. Report on the International Workshop on the Biopharmaceutics Classification System (BCS): scientific and regulatory aspects in practice. J Pharm Pharm Sci 2002;5:1-4. (Pubitemid 34463344)
17. Verbeeck RK, Junginger HE, Midha KK, Shah VP, Barends DM. Biowaiver monographs for immediate release solid oral dosage forms based on Biopharmaceutics Classification System (BCS) literature data: Chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride. J Pharm Pharm Sci 2005;94:1389-95. (Pubitemid 41168671)
18. Nagesh XB, Murti V. BCS Class IV Drugs: Develop or Discard? AAPS annual meeting and Exposition; 2007 Nov 11-15; San Diego Convention Centers, San Diego, CA.
19. Bala I, Bhardwaj V, Hariharan S, Sitterberg J, Bakowsky U, Ravi Kumar MN. Design of biodegradable nanoparticles: A novel approach to encapsulating poorly soluble phytochemical ellagic acid. Nanotechnology 2005;16:2819-22. (Pubitemid 41677035)
20. Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying Drug Delivery Systems (SEDDS) of Coenzyme Q 10: Formulation development and bioavailability assessment. Int J Pharm 2001;212:233-46. (Pubitemid 32119449)
21. Sharma P, Varma MV, Chawla HP, Panchagnula R. In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies. II Farmaco 2005;60:874-83. (Pubitemid 41586261)
22. Gohel MC, Mehta NR. An audit of recent inputs on biopharmaceutical classification system [online]. Pharmaceut Rev. Available from: http://www.pharmainfo.net/reviews/audit-recent-inputs-biopharmaceutical- classification-system. [last cited on 2005 Jan 09].
23. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, et al. Biopharmaceutics classification system: The scientific basis for biowaiver extension. Pharm Res 2002;19:921-5. (Pubitemid 34804232)
24. Wilding I. Evolution of the Biopharmaceutics Classification System (BCS) to Modified Release (MR) formulations: What do we need to consider? Eur J Pharm Sci 1999;8:157-9. (Pubitemid 29324642)
25. Devane J. Oral drug delivery technology: Addressing the solubility/permeability paradigm. Pharmaceut Technol 1998;22:68-80. (Pubitemid 28527454)
26. Lennerns H, Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: Current status and future extension. J Pharm Pharmacol 2005;57:273-85. (Pubitemid 40326200)
27. Varma MV, Khandavilli S, Ashokraj Y, Jain A, Dhanikula A, Sood A, et al. Biopharmaceutic classification system: A scientific framework for pharmacokinetic optimization in drug research. Curr Drug Metab 2004;5:375-88. (Pubitemid 39276602)
28. Bergestrom CA, Lazorova L, Avdeef A, Luthman K, Artursson P. Absorption classification of oral drugs based on molecular surface properties. J Med Chem 2003;46:558-70. (Pubitemid 36182757)
29. Rinaki E, Valsami G, Macheras, P. Quantitative biopharmaceutics classification system: The central role of dose/solubility ratio. Pharm Res 2003;20:1917-25. (Pubitemid 38005521)
30. Fagerholm U. Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS). J Pharm Pharmacol 2007;59:751-7. (Pubitemid 47051087)